Janssen China Announces Launch of Innovative Drug DARZALEX FASPRO® in China for AL Amyloidosis and Multiple Myeloma

November 9th update: Janssen China recently announced the launch of its innovative drug, XEPIAO® (Daratumumab Injection (Subcutaneous Injection), English trade name: DARZALEX FASPRO®) in China. It is used in combination with bortezomib, cyclophosphamide, and dexamethasone for treating newly diagnosed patients with primary light chain amyloidosis. Additionally, it is also indicated for the treatment of multiple myeloma, including newly diagnosed patients who are not eligible for autologous stem cell transplantation and patients with relapsed disease after first-line or multiple lines of therapy.